A large new clinical trial has found that high-dose vitamin D3 does not significantly improve survival for patients with metastatic colorectal cancer, countering earlier hopes that the supplement could boost chemotherapy’s effectiveness. The trial, known as SOLARIS and published in JAMA, is one of the most rigorous tests yet of a theory that had circulated in cancer research for years.
What did the SOLARIS trial actually test
Researchers enrolled 455 patients with metastatic colorectal cancer in a double-blind, multicenter study and randomly assigned them to receive either a high dose or a standard dose of vitamin D3 alongside their regular chemotherapy. The goal was to see whether the higher dose could extend progression-free survival, the length of time before a patient’s cancer worsens.
Did high-dose vitamin D improve survival
Largely, no. Patients on the high dose had a median progression-free survival of 11.8 months, compared with 10.3 months for those on the standard dose. Researchers found no meaningful difference in overall survival or in how patients responded to treatment between the two groups, undercutting the idea that simply raising the dose would meaningfully change outcomes.
Why does colorectal cancer stage matter so much here
Survival outcomes for colorectal cancer vary enormously depending on when it is caught. Cancer found at stage 1 carries a five-year survival rate near 90%, largely because surgery and chemotherapy can still remove or contain it. Once the disease spreads, or metastasizes, that survival rate falls to roughly 14%, which is part of why researchers have been searching for any treatment, including vitamin D, that might slow progression in these harder to treat cases.
Is there any group that seemed to benefit
One exception stood out. Patients whose primary tumors were on the left side of the colon showed a median progression-free survival of 13.8 months on the high dose, compared with 10.2 months on the standard dose. Researchers describe this finding as exploratory, meaning it emerged from a subgroup analysis rather than the trial’s main question, and it needs to be confirmed in future studies before it changes how doctors treat patients.
Why do negative results like this matter
Dr. Ketan Thanki, a colorectal surgeon who was not involved in the study, said negative findings serve an important purpose in medical research. Without them, the published literature tends to skew toward positive results, which can mislead doctors and researchers about what actually works. A clearly negative trial like SOLARIS helps redirect funding and attention toward approaches more likely to help patients.
Did the trial have any limitations
Thanki raised one notable question, pointing out that the study compared two doses of vitamin D3 rather than comparing vitamin D3 against no supplementation at all. Without a group that received none, it remains unclear how much of an effect vitamin D3 has at any dose. He suggested future research test a wider range of doses across different patient populations to settle that question.
Should patients take vitamin D during chemotherapy
Right now, vitamin D3 supplementation is not part of the standard treatment plan for patients undergoing chemotherapy for metastatic colorectal cancer, even at low doses, and this trial does not change that. Patients considering supplements during cancer treatment should talk with their oncologist first, since dosing, drug interactions and individual health factors all play a role.
What comes next for researchers
The SOLARIS results do not close the book on vitamin D and cancer, they narrow the question. Future trials are likely to focus on the left-sided tumor subgroup and on comparing supplementation against a true no-treatment baseline, work that could eventually clarify whether vitamin D has a real, targeted role in colorectal cancer care rather than a broad one.
This is a developing area of medical research, and anyone facing a cancer diagnosis should rely on guidance from their own care team rather than general reporting when making treatment decisions.
